

# Mark Clemons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2104143/publications.pdf>

Version: 2024-02-01

152  
papers

3,958  
citations

172457

29  
h-index

149698

56  
g-index

153  
all docs

153  
docs citations

153  
times ranked

6363  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review. <i>Clinical Breast Cancer</i> , 2022, 22, e362-e373.	2.4	8
2	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. <i>Supportive Care in Cancer</i> , 2022, 30, 3977-3984.	2.2	5
3	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 787-800.	1.6	44
4	Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience. <i>Supportive Care in Cancer</i> , 2022, 30, 4437-4446.	2.2	5
5	Attitudes towards open-label versus placebo-control designs in oncology randomized trials: A survey of medical oncologists. <i>Journal of Evaluation in Clinical Practice</i> , 2022, , .	1.8	2
6	Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REACT-RETT trial). <i>Cancer Research</i> , 2022, 82, OT1-01-01-OT1-01-01.	0.9	1
7	VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models. <i>British Journal of Cancer</i> , 2022, , .	6.4	0
8	Management Strategies for Older Patients with Low-Risk Early-Stage Breast Cancer: A Physician Survey. <i>Current Oncology</i> , 2022, 29, 1-13.	2.2	2
9	Using machine learning to predict individual patient toxicities from cancer treatments. <i>Supportive Care in Cancer</i> , 2022, 30, 7397-7406.	2.2	2
10	Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. <i>Current Oncology</i> , 2022, 29, 4125-4137.	2.2	2
11	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 142, 132-140.	2.8	42
12	A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 533-547.	2.5	4
13	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. <i>Journal of Bone Oncology</i> , 2021, 26, 100339.	2.4	10
14	A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 3113-3120.	2.2	3
15	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021, 29, 2509-2517.	2.2	17
16	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. <i>Journal of Bone Oncology</i> , 2021, 26, 100343.	2.4	6
17	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. <i>Supportive Care in Cancer</i> , 2021, 29, 5787-5795.	2.2	6
18	Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 477-486.	2.5	6

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. <i>Current Oncology</i> , 2021, 28, 1338-1347.	2.2	10
20	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. <i>Journal of Bone Oncology</i> , 2021, 27, 100351.	2.4	4
21	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. <i>Supportive Care in Cancer</i> , 2021, 29, 6903-6912.	2.2	6
22	Lost in Transition? Thoughts on Retirement, Part 2. "Should I Stay or Should I Go Now?" <i>Oncologist</i> , 2021, 26, e1290-e1295.	3.7	3
23	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. <i>European Journal of Cancer</i> , 2021, 149, 117-127.	2.8	7
24	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 1847-1856.	2.2	3
25	The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 97, 102188.	7.7	9
26	Developing patient-centred strategies to optimize the management of vasomotor symptoms in breast cancer patients: a survey of health care providers. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 343-350.	2.5	3
27	Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting. <i>Supportive Care in Cancer</i> , 2021, 29, 7837-7843.	2.2	1
28	Breast cancer in Indigenous women living in Canada: a scoping review protocol. <i>JBIC Evidence Synthesis</i> , 2021, 19, 3412-3422.	1.3	0
29	Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?. <i>Current Oncology</i> , 2021, 28, 2523-2528.	2.2	2
30	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. <i>Breast</i> , 2021, 58, 42-49.	2.2	4
31	De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102254.	7.7	10
32	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 295-305.	2.5	1
33	DECOLONIZING CANCER CARE IN CANADA. <i>Journal of Cancer Policy</i> , 2021, 30, 100309.	1.4	5
34	Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. <i>Journal of Bone Oncology</i> , 2021, 30, 100388.	2.4	6
35	A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction. <i>Current Oncology</i> , 2021, 28, 184-195.	2.2	8
36	The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design. <i>Current Oncology</i> , 2021, 28, 3959-3977.	2.2	5

#	ARTICLE	IF	CITATIONS
37	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. <i>Current Oncology</i> , 2021, 28, 5073-5083.	2.2	5
38	Experiences and Perceptions of Older Adults with Lower-Risk Hormone Receptor-Positive Breast Cancer about Adjuvant Radiotherapy and Endocrine Therapy: A Patient Survey. <i>Current Oncology</i> , 2021, 28, 5215-5226.	2.2	6
39	Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trial. <i>Health Science Reports</i> , 2021, 4, e443.	1.5	1
40	Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 889-892.	1.8	9
41	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020, 112, 698-707.	6.3	48
42	Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. <i>Clinical Breast Cancer</i> , 2020, 20, 61-67.	2.4	7
43	Prospective randomised controlled trial using the Rethinking Clinical Trials (REaCT) platform and National Surgical Quality Improvement Program (NSQIP) to compare no preparation versus preoperative oral antibiotics alone for surgical site infection rates in elective colon surgery: a protocol. <i>BMI Open</i> , 2020, 10, e036866.	1.9	5
44	Population Trends in Lobular Carcinoma of the Breast: The Ontario Experience. <i>Annals of Surgical Oncology</i> , 2020, 27, 4711-4719.	1.5	12
45	&lt;p&gt;Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients&lt;/p&gt;. <i>Journal of Pain Research</i> , 2020, Volume 13, 313-321.	2.0	13
46	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4891-4899.	2.2	17
47	Comparing Interventions for Management of Hot Flashes in Patients With Breast and Prostate Cancer: A Systematic Review With Meta-Analyses. , 2020, 47, E86-E106.		10
48	Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC). <i>Supportive Care in Cancer</i> , 2019, 27, 1345-1354.	2.2	5
49	A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 327-335.	2.5	51
50	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 337-345.	2.5	7
51	Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 347-356.	2.5	9
52	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). <i>Breast Cancer Research and Treatment</i> , 2019, 177, 93-101.	2.5	15
53	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 507-517.	2.5	23
54	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 196-204.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Why “Reply All” Can Push All the Wrong Buttons. <i>Oncologist</i> , 2019, 24, e643-e645.	3.7	2
56	Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 42.	5.2	13
57	Benefits and harms of medical cannabis: a scoping review of systematic reviews. <i>Systematic Reviews</i> , 2019, 8, 320.	5.3	97
58	Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2019, 19, e40-e47.	2.4	7
59	A prospective intervention to improve happiness and reduce burnout in oncologists. <i>Supportive Care in Cancer</i> , 2019, 27, 1563-1572.	2.2	6
60	Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2018, 26, 2323-2331.	2.2	6
61	A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 371-379.	2.5	7
62	The importance of greater speed in drug development for advanced malignancies. <i>Cancer Medicine</i> , 2018, 7, 1824-1836.	2.8	23
63	Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information. <i>Supportive Care in Cancer</i> , 2018, 26, 1-2.	2.2	0
64	Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. <i>Supportive Care in Cancer</i> , 2018, 26, 3073-3081.	2.2	12
65	Guidelines versus individualized care for the management of CINV. <i>Supportive Care in Cancer</i> , 2018, 26, 11-17.	2.2	10
66	Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	7
67	De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?. <i>Journal of Oncology Practice</i> , 2018, 14, 465-467.	2.5	5
68	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154.	2.8	52
69	Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial). <i>PLoS ONE</i> , 2018, 13, e0199297.	2.5	2
70	Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 607-620.	2.5	37
71	Poor outcomes after venous thromboembolism in cancer patients: It's time to change practice. <i>Thrombosis Research</i> , 2018, 171, 177-178.	1.7	0
72	Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. <i>Supportive Care in Cancer</i> , 2017, 25, 1881-1886.	2.2	8

#	ARTICLE	IF	CITATIONS
73	Predatory Invitations from Journals: More Than Just a Nuisance?. <i>Oncologist</i> , 2017, 22, 236-240.	3.7	42
74	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. <i>Supportive Care in Cancer</i> , 2017, 25, 2505-2513.	2.2	5
75	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	10.7	427
76	Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy. <i>Npj Breast Cancer</i> , 2017, 3, 47.	5.2	3
77	Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel+cyclophosphamide chemotherapy for breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 1-10.	2.5	22
78	A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 1-6.	1.9	13
79	Reply to T.J. Powles et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2720-2721.	1.6	0
80	Is This Conference for Real? Navigating Presumed Predatory Conference Invitations. <i>Journal of Oncology Practice</i> , 2017, 13, 410-413.	2.5	20
81	Physician "Out of Office" Alert: Does It Work?. <i>Current Oncology</i> , 2017, 24, 176-179.	2.2	1
82	Driving quality improvement with public reporting: Use of imaging tests outside guidelines for early-stage breast cancer in Ontario.. <i>Journal of Clinical Oncology</i> , 2017, 35, 193-193.	1.6	1
83	A Simple Approach for Eliminating Spam. <i>Current Oncology</i> , 2016, 23, 75-76.	2.2	10
84	Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, e1016-e1024.	2.5	26
85	De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer. <i>Current Oncology</i> , 2016, 23, 77-78.	2.2	7
86	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). <i>Journal of Bone Oncology</i> , 2016, 5, 57-62.	2.4	9
87	Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer – a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 3633-3650.	2.2	33
88	Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions. <i>Journal of Bone Oncology</i> , 2016, 5, 180-184.	2.4	1
89	Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 91-99.	2.5	26
90	Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016, 50, 183-193.	7.7	39

#	ARTICLE	IF	CITATIONS
91	Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patientsâ€”A Systematic Review. <i>Clinical Breast Cancer</i> , 2016, 16, 456-470.	2.4	26
92	Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast. <i>Breast Journal</i> , 2016, 22, 45-53.	1.0	14
93	Rethinking end-points for bone-targeted therapy in advanced cancer. <i>European Journal of Cancer</i> , 2016, 63, 105-109.	2.8	6
94	Risk Modelâ€”Guided Antiemetic Prophylaxis vs Physicianâ€™s Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 225.	7.1	37
95	A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 139-144.e3.	2.4	19
96	Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. <i>Supportive Care in Cancer</i> , 2016, 24, 1563-1569.	2.2	19
97	Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 337-344.	2.5	15
98	Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review. <i>Clinical Colorectal Cancer</i> , 2016, 15, e117-e123.	2.3	19
99	Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapyâ€”a systematic review. <i>Supportive Care in Cancer</i> , 2016, 24, 1583-1594.	2.2	29
100	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1097-1105.	2.2	81
101	Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting. <i>Journal of Bone Oncology</i> , 2015, 4, 54-58.	2.4	17
102	Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. <i>Journal of Bone Oncology</i> , 2015, 4, 47-53.	2.4	7
103	Treatment choices for patients with invasive lobular breast cancer: a doctor survey. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 740-748.	1.8	12
104	Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer. <i>International Journal of Surgical Oncology</i> , 2015, 2015, 1-9.	0.6	10
105	Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 1-8.	2.5	33
106	Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapyâ€”a survey of health care providers and patients. <i>Supportive Care in Cancer</i> , 2015, 23, 3269-3275.	2.2	17
107	Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?. <i>Oncologist</i> , 2015, 20, 576-583.	3.7	62
108	Imaging for metastatic disease in patients with newly diagnosed breast cancer: are doctor's perceptions in keeping with the guidelines?. <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 67-73.	1.8	18



#	ARTICLE	IF	CITATIONS
109	Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. <i>Cmaj</i> , 2015, 187, E387-E397.	2.0	29
110	Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses. <i>Systematic Reviews</i> , 2015, 4, 114.	5.3	16
111	Identification of genomic signatures in circulating tumor cells from breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 332-344.	5.1	54
112	Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review. <i>Oncologist</i> , 2015, 20, 210-223.	3.7	91
113	Are Physicians Choosing Wisely When Imaging for Distant Metastases in Women With Operable Breast Cancer?. <i>Journal of Oncology Practice</i> , 2015, 11, 62-68.	2.5	30
114	The incidence and clinical impact of bone metastases in non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 89, 197-202.	2.0	84
115	Defining optimal control of chemotherapy-induced nausea and vomiting based on patients' experience. <i>Supportive Care in Cancer</i> , 2015, 23, 3341-3359.	2.2	37
116	Surviving Surveys. <i>Journal of Oncology Practice</i> , 2015, 11, 44-46.	2.5	9
117	Use of Preoperative Magnetic Resonance Imaging for Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1238.	7.1	43
118	Dosing Strategies of Bone-Targeting Agents. <i>JAMA Internal Medicine</i> , 2015, 175, 1864.	5.1	4
119	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. <i>Cancer Research</i> , 2015, 75, 3479-3491.	0.9	375
120	Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations. <i>Clinical Breast Cancer</i> , 2015, 15, 421-425.	2.4	33
121	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. <i>Cell Metabolism</i> , 2015, 22, 577-589.	16.2	430
122	Chemotherapy in the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older. <i>Journal of Geriatric Oncology</i> , 2015, 6, 395-400.	1.0	31
123	Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer – An inspection of the evidence base informing clinical decision-making. <i>Cancer Treatment Reviews</i> , 2015, 41, 951-959.	7.7	12
124	Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality. <i>PLoS ONE</i> , 2014, 9, e110469.	2.5	34
125	Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. <i>Oncology Letters</i> , 2014, 7, 866-870.	1.8	8
126	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. <i>SpringerPlus</i> , 2014, 3, 577.	1.2	18



#	ARTICLE	IF	CITATIONS
127	Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects. <i>Oncologist</i> , 2014, 19, 127-134.	3.7	72
128	Long-term benefits versus side-effects from bone-targeted therapies for cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 420-428.	1.3	10
129	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 615-624.	2.5	25
130	Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. <i>SpringerPlus</i> , 2014, 3, 176.	1.2	27
131	Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. <i>Journal of Bone Oncology</i> , 2014, 3, 1-4.	2.4	5
132	SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.. <i>Journal of Clinical Oncology</i> , 2014, 32, 558-558.	1.6	12
133	Staging imaging for metastatic disease in patients with early-stage breast cancer: What do physicians think of the ASCO top-5 recommendation?. <i>Journal of Clinical Oncology</i> , 2014, 32, 6596-6596.	1.6	2
134	De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 77-83.	2.4	24
135	Does estrogen play a role in response to adjuvant bone-targeted therapies?. <i>Journal of Bone Oncology</i> , 2013, 2, 167-173.	2.4	6
136	A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. <i>Journal of Bone Oncology</i> , 2013, 2, 123-131.	2.4	21
137	Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. <i>Journal of Bone Oncology</i> , 2013, 2, 105-109.	2.4	18
138	Incidence and consequences of bone metastases in lung cancer patients. <i>Journal of Bone Oncology</i> , 2013, 2, 22-29.	2.4	78
139	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. <i>Journal of Bone Oncology</i> , 2013, 2, 154-157.	2.4	15
140	Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. <i>Journal of Bone Oncology</i> , 2013, 2, 38-46.	2.4	14
141	Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 436-442.	1.3	33
142	Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. <i>Journal of Clinical Medicine</i> , 2013, 2, 67-88.	2.4	7
143	Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 531-531.	1.6	13
144	Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?. <i>Journal of Bone Oncology</i> , 2012, 1, 12-17.	2.4	12

#	ARTICLE	IF	CITATIONS
145	Content validation of the EORTC QLQ-BN20+2 with patients and health care professionals to assess quality of life in brain metastases. <i>Journal of Radiation Oncology</i> , 2012, 1, 397-409.	0.7	4
146	Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 453-457.	2.5	10
147	Continued suppression of bone turnover following a single dose of zoledronic acid: Time to re-think dosing intervals in the management of bone metastases?. <i>Journal of Clinical Oncology</i> , 2012, 30, 9111-9111.	1.6	2
148	Immune Therapy for Breast Cancer in 2010â€”Hype or Hope?. <i>Current Oncology</i> , 2011, 18, 623.	2.2	31
149	Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 177-186.	2.5	13
150	Prevalence and Severity of Urogenital Symptoms in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer. <i>Clinical Breast Cancer</i> , 2009, 9, 108-117.	2.4	68
151	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. <i>European Journal of Cancer</i> , 2009, 45, 1146-1152.	2.8	108
152	Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?. <i>Oncologist</i> , 2008, 13, 222-231.	3.7	67